NASDAQ:SGHT Sight Sciences (SGHT) Stock Price, News & Analysis $3.57 +0.21 (+6.25%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Sight Sciences Stock (NASDAQ:SGHT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sight Sciences alerts:Sign Up Key Stats Today's Range$3.30▼$3.6450-Day Range$3.36▼$6.1852-Week Range$3.12▼$8.45Volume470,053 shsAverage Volume203,060 shsMarket Capitalization$181.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.12Consensus RatingHold Company OverviewSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Read More… Sight Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks61st Percentile Overall ScoreSGHT MarketRank™: Sight Sciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 424th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingSight Sciences has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageSight Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sight Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sight Sciences are expected to grow in the coming year, from ($1.01) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sight Sciences is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sight Sciences is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSight Sciences has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.35% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Sight Sciences has recently increased by 0.73%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSight Sciences does not currently pay a dividend.Dividend GrowthSight Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.35% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Sight Sciences has recently increased by 0.73%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Sight Sciences this week, compared to 2 articles on an average week.Search Interest4 people have searched for SGHT on MarketBeat in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sight Sciences insiders have sold 886.86% more of their company's stock than they have bought. Specifically, they have bought $58,232.00 in company stock and sold $574,666.00 in company stock.Percentage Held by Insiders28.90% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sight Sciences' insider trading history. Receive SGHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SGHT Stock News HeadlinesSight Sciences, Inc. (NASDAQ:SGHT) EVP Buys $19,250.00 in StockDecember 10, 2024 | insidertrades.comManohar K. Raheja Buys 3,376 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) StockDecember 6, 2024 | insidertrades.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.December 21, 2024 | Crypto Swap Profits (Ad)Manohar K. Raheja Purchases 4,624 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) StockDecember 4, 2024 | insidertrades.comSight Sciences does BIA of TearCare to treat MGD-associated DED in USDecember 21 at 1:45 AM | markets.businessinsider.comSight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment OptionsDecember 19 at 4:05 PM | globenewswire.comSight Sciences price target lowered to $4.60 from $5.80 at CitiDecember 11, 2024 | markets.businessinsider.comUBS Initiates Coverage of Sight Sciences (SGHT) with Buy RecommendationDecember 7, 2024 | msn.comSee More Headlines SGHT Stock Analysis - Frequently Asked Questions How have SGHT shares performed this year? Sight Sciences' stock was trading at $5.16 at the beginning of the year. Since then, SGHT stock has decreased by 30.8% and is now trading at $3.57. View the best growth stocks for 2024 here. How were Sight Sciences' earnings last quarter? Sight Sciences, Inc. (NASDAQ:SGHT) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm earned $20.16 million during the quarter, compared to analysts' expectations of $20.41 million. Sight Sciences had a negative trailing twelve-month return on equity of 47.28% and a negative net margin of 63.30%. When did Sight Sciences IPO? Sight Sciences (SGHT) raised $150 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,980,000 shares at a price of $20.00-$23.00 per share. Who are Sight Sciences' major shareholders? Sight Sciences' top institutional investors include Geode Capital Management LLC (1.54%), State Street Corp (1.27%), Jacobs Levy Equity Management Inc. (0.41%) and B. Riley Wealth Advisors Inc. (0.38%). Insiders that own company stock include Paul Badawi, D1 Capital Partners LP, David Badawi, Staffan Encrantz, Matthew Link, Sam Boong Park, Jeremy B Hayden and Manohar K Raheja. View institutional ownership trends. How do I buy shares of Sight Sciences? Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sight Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sight Sciences investors own include American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings11/07/2024Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:SGHT CUSIPN/A CIK1531177 Webwww.sightsciences.com Phone877-266-1144FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$5.12 High Stock Price Target$5.50 Low Stock Price Target$4.60 Potential Upside/Downside+43.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,550,000.00 Net Margins-63.30% Pretax Margin-63.04% Return on Equity-47.28% Return on Assets-32.72% Debt Debt-to-Equity Ratio0.36 Current Ratio10.18 Quick Ratio9.74 Sales & Book Value Annual Sales$79.54 million Price / Sales2.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book1.45Miscellaneous Outstanding Shares50,755,000Free Float36,087,000Market Cap$181.20 million OptionableOptionable Beta2.58 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:SGHT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredWhat most folks don’t know about oil (BIG missed opportunity)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Go...ProsperityPub | SponsoredHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buyi...Insiders Exposed | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—wit...Darwin | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sight Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.